By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ablynx 

Technologiepark 4

Ghent  Zwijnaarde  9052  Belgium
Phone: 32-0-9-261-06-32 Fax: 32-0-9-261-06-28


SEARCH JOBS








Company News
Novel Nanobody To Start Clinical Development In Osteoarthritis - Ablynx (ABLYF) To Receive €15 Million Milestone Payment 5/22/2017 10:40:28 AM
Ablynx (ABLYF) Reports Financial Results For The First Three Months Of 2017 And A Year-To-Date Business Update 5/11/2017 12:47:40 PM
Ablynx (ABLYF) Completes Patient Recruitment In Its Phase III Hercules Study Of Caplacizumab For The Treatment Of aTTP 5/2/2017 11:02:06 AM
Ablynx (ABLYF) Announces Warrant Exercise 4/21/2017 8:37:51 AM
AbbVie (ABBV) Abandons Arthritis Pact With Ablynx (ABLYF) 10/20/2016 5:36:17 AM
Ablynx (ABLYF) Reports Compelling Topline Phase Ilb Study Results With Its Anti-Il-6r Nanobody, Vobarilizumab, In RA Patients, Confirming Its Best-In-Class Potential 8/9/2016 10:14:09 AM
AbbVie (ABBV)'s $175 Million Gamble Pays Off as Ablynx (ABLYF) RA Drug Meets Goal in Phase II Study 7/8/2016 7:05:48 AM
Ablynx (ABLYF) To Exercise Option To License Vectura (VEC.L)’s FOX Device For Use In Its Forthcoming Phase IIb Efficacy Study Of Its Inhaled Anti-RSV Nanobody (ALX-0171) 6/28/2016 11:42:20 AM
Ablynx (ABLYF) Release: Publication In Accordance With Article 15 Of The Belgian Law Of 2 May 2007 On The Publication Of Major Shareholdings (The "Transparency Law") 6/13/2016 7:40:43 AM
Ablynx (ABLYF) Reports Positive Top Line Results For Its Anti-RSV Nanobody (ALX-0171) Inhaled Using Vectura (VEC.L)’s FOX Device In A Phase I/IIa Study In Infants Hospitalized With RSV Infection 5/3/2016 9:09:07 AM
12345678910...
//-->